为了正常的体验网站,请在浏览器设置里面开启Javascript功能!
首页 > 2012.9.24--FDA最新ANDA:活性物质和药品的稳定性测试指南草案

2012.9.24--FDA最新ANDA:活性物质和药品的稳定性测试指南草案

2012-09-26 6页 pdf 960KB 133阅读

用户头像

is_620441

暂无简介

举报
2012.9.24--FDA最新ANDA:活性物质和药品的稳定性测试指南草案 Zhulikou431 作品, 丁香园论坛首发 Guidance for Industry 行业指南 ANDAs: Stability Testing of Drug Substances and Products ANDA:活性物质和药品的稳定性测试 DRAFT GUIDANCE 指南草案 This guidance document is being distributed for comment purposes only. Comments and suggestions re...
2012.9.24--FDA最新ANDA:活性物质和药品的稳定性测试指南草案
Zhulikou431 作品, 丁香园论坛首发 Guidance for Industry 行业指南 ANDAs: Stability Testing of Drug Substances and Products ANDA:活性物质和药品的稳定性测试 DRAFT GUIDANCE 指南草案 This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact (CDER) Radhika Rajagopalan 240-2768546. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2012 OGD Zhulikou431 作品, 丁香园论坛首发 Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Silver Spring, MD 20993 Phone: 301-796-3400; Fax: 301-847-8714 druginfo@fda.hhs.gov http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2012 OGD Zhulikou431 作品, 丁香园论坛首发 TABLE OF CONTENTS目录 I. INTRODUCTION介绍 II. BACKGROUND背景 III. DISCUSSION 讨论 Zhulikou431 作品, 丁香园论坛首发 行业指南 ANDA:活性物质和药品稳定性测试 上面这段是废话,不翻译。 注释 1:这份指南由仿制药办公室、FDA 的 CDER 的制药科学办公室起草。 I. 介绍 这份指南建议依据 FDCA 的 505(j)条款递交的 ANDA 申请和支持 ANDA 的 DMF 文 件,应该遵循 ICH 稳定性指南中的建议。 Zhulikou431 作品, 丁香园论坛首发 上面这段是废话,不翻译。 II.背景 在过去的这些年,仿制药办公室(OGD)已经收到大量关于 ANDA 相关稳定性数 据要求的申请。仿制药办公室目前发布的指南包括 1995 年的工业信件,表明仿 制药办公室将接受 ICH 推荐的关于稳定性研究的长期室温条件(就是 25±2℃, 60±5%RH)。尽管在那个时候,指南文本内容是足够使用的,但是这条建议对于 支持 ANDA 稳定性研究的基础,已经不再足够。 4. Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products. 5. Q1E Evaluation of Stability Data These will be referred to in the discussion that follows as ICH stability guidances. 下面这些存在的ICH指南阐述了关于新活性物质和药品稳定性研究问题: 1.Q1A(R2) 2.Q1B 3.Q1C 4.Q1D 5.Q1E 在讨论中将提到要遵守ICH关于稳定性研究的指南。 III. DISCUSSION讨论 Although the ICH stability guidances were developed by ICH to provide guidance on the information that should be provided in new drug applications to ensure the stability of new drug substances and drug Zhulikou431 作品, 丁香园论坛首发 products, we believe the recommendations should be applied to ANDAs as well. 尽管由ICH起草的ICH关于稳定性指南为新药申请需要提交信息提供指南,以确 保新活性物质和药品的稳定性,我们认为这些建议也应该适用于ANDA申请。 When following the ICH stability recommendations, the applicant should: 当采用ICH关于稳定性建议时,申请者应该: 1. Submit data from three pilot scale batches or two pilot batches and one small scale batch. If the size of the pilot does not follow ICH recommendations, the applicant should provide a justification. 递交的数据应该来自3批中试批次,或者2批中试批次和一个较小批次。如果中 试批次规模不符合ICH建议,申请者应该提供论证说明。 2. At the time of submission, provide 6 months of data that include accelerated and long-term conditions. FDA recommends following ICH with respect to utilization of intermediate conditions to support shelf-life. 在递交的时候,需要提交6个月数据,包括加速试验和长期试验数据。FDA建议 遵循ICH关于采用中间条件以支持有效期的做法。 3. Use multiple lots of drug substance as appropriate. 根据情况,使用多批次活性物质。 4. Manufacture and package the drug product using principles that are representative of the commercial process. 药品的制造和包装的原则是可以代表商业化生产工艺。 5. Provide a fully packaged primary exhibit batch. 需要提供一个完整包装的原始展示批次。 6. Use three batches when using bracketing and matrixing designs under ICH Q1D. 当根据ICH Q1D指南的括号法和矩阵法进行设计时,要使用3批次数据。 7. Provide statistical analysis of the data as appropriate, in accordance with ICH Q1E, Appendix A. 根据情况,根据ICH Q1E指南附录A来提供数据统计分析。 If you choose to deviate from the above recommendations, you should justify the approach you are taking. 如果你选择不采用上述建议,你应该提供论证来说明你采用的方法。 We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at http://www fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/defa ult htm. 注释2:我们定期更新指南,为了确保你获得最新版本指南,请核实FDA指南网 址: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Gui dances/default htm.
/
本文档为【2012.9.24--FDA最新ANDA:活性物质和药品的稳定性测试指南草案】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑, 图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。 本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。 网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。

历史搜索

    清空历史搜索